{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:46:14Z","timestamp":1777502774878,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.tjpad.2025.100391","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:24:20Z","timestamp":1761528260000},"page":"100391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of recent approvals on future alzheimer\u2019s disease clinical development: Statistical considerations for combination trials"],"prefix":"10.1016","volume":"12","author":[{"given":"Samuel P","family":"Dickson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Mallinckrodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0176-9184","authenticated-orcid":false,"given":"Aaron H","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Nisenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard M","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-7727","authenticated-orcid":false,"given":"Suzanne B","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100391_bib0001","series-title":"Alzheimer\u2019s Disease","article-title":"Contributing Factors of Neurodegeneration in Alzheimer\u2019s Disease","author":"Tailor","year":"2019"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100391_bib0002","first-page":"1","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.tjpad.2025.100391_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Res Rev"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100391_bib0004","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100391_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100391_bib0006","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"Pt A","key":"10.1016\/j.tjpad.2025.100391_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mad.2016.05.005","article-title":"Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer\u2019s disease brain","volume":"161","author":"Abolhassani","year":"2017","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.tjpad.2025.100391_bib0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13195-022-00996-8","article-title":"Glucose metabolism and AD: evidence for a potential diabetes type 3","volume":"14","author":"Gonz\u00e1lez","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100391_bib0009","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12916-023-02852-4","article-title":"Combination therapies for cancer: challenges and opportunities","volume":"21","author":"Zhou","year":"2023","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100391_bib0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100391_bib0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12981-021-00401-8","article-title":"Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States","volume":"18","author":"Dub\u00e9","year":"2021","journal-title":"AIDS Res Ther"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100391_bib0012","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14656566.2011.567001","article-title":"Combination antiretroviral therapy","volume":"12","author":"Domingo","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.tjpad.2025.100391_bib0013","series-title":"Pac Symp Biocomput Pac Symp Biocomput","first-page":"68","article-title":"Characteristics of drug combination therapy in oncology by analyzing clinical trial data on clinicaltrials.Gov","author":"WU","year":"2015"},{"issue":"9932","key":"10.1016\/j.tjpad.2025.100391_bib0014","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/S0140-6736(14)60614-0","article-title":"Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study","volume":"383","author":"Giles","year":"2014","journal-title":"Lancet L Engl"},{"issue":"1\u20132","key":"10.1016\/j.tjpad.2025.100391_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100391_bib0016","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/08919887211044746","article-title":"Alzheimer\u2019s Disease: efficacy of mono- and Combination therapy. A systematic review","volume":"35","author":"Knorz","year":"2022","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100391_bib0017","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/13607860902749057","article-title":"Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer\u2019s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial","volume":"13","author":"Yancheva","year":"2009","journal-title":"Aging Ment Health"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100391_bib0018","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.clinthera.2007.10.012","article-title":"Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer\u2019s disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients","volume":"29","author":"Sun","year":"2007","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100391_bib0019","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/gps.4074","article-title":"The effects of combine treatment of memantine and donepezil on Alzheimer\u2019s disease patients and its relationship with cerebral blood flow in the prefrontal area","volume":"29","author":"Araki","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100391_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100391_bib0021","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100391_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/156720508783884576","article-title":"Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial","volume":"5","author":"Porsteinsson","year":"2008","journal-title":"Curr Alzheimer Res"},{"issue":"1\u20133","key":"10.1016\/j.tjpad.2025.100391_bib0023","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000295663","article-title":"Treatment of Alzheimer\u2019s disease with a cholinesterase inhibitor combined with antioxidants","volume":"7","author":"Cornelli","year":"2010","journal-title":"Neurodegener Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100391_bib0024","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1185\/03007995.2011.582484","article-title":"Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer\u2019s disease: a multicenter, randomized, open-label, parallel-group study","volume":"27","author":"Choi","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100391_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100391_bib0026","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trci.2015.10.001","article-title":"Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug na\u00efve patients with mild-to-moderate Alzheimer\u2019s disease","volume":"1","author":"Peters","year":"2015","journal-title":"Alzheimers Dement N N"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100391_bib0027","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of Idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer Disease: three randomized clinical trials","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100391_bib0028","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/JAD-150414","article-title":"Effects of the acetylcholine release agent ST101 with Donepezil in Alzheimer\u2019s disease: a randomized phase 2 study","volume":"48","author":"Gauthier","year":"2015","journal-title":"J Alzheimers Dis JAD"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100391_bib0029","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12603-012-0062-8","article-title":"A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI","volume":"16","author":"Peters","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100391_bib0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/jcp.0b013e31814b98c1","article-title":"Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer\u2019s dementia? A double-blind, placebo-controlled clinical trial","volume":"27","author":"Mowla","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100391_bib0031","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100391_bib0032","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100391_bib0033","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s43587-023-00404-2","article-title":"Towards a future where Alzheimer\u2019s disease pathology is stopped before the onset of dementia","volume":"3","author":"van der Flier","year":"2023","journal-title":"Nat Aging"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100391_bib0034","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2014.02.002","article-title":"An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer\u2019s disease","volume":"10","author":"Langbaum","year":"2014","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100391_bib0035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100391_bib0036","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jalz.2016.01.002","article-title":"Longitudinal decline in mild-to-moderate Alzheimer\u2019s disease: analyses of placebo data from clinical trials","volume":"12","author":"Thomas","year":"2016","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100391_bib0037","doi-asserted-by":"crossref","first-page":"E170","DOI":"10.1073\/pnas.1210419110","article-title":"Defining principles of combination drug mechanisms of action","volume":"110","author":"Pritchard","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"18","key":"10.1016\/j.tjpad.2025.100391_bib0038","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1158\/1078-0432.CCR-07-1385","article-title":"Targeted agents: the rules of combination","volume":"13","author":"Kwak","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.tjpad.2025.100391_bib0039","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J Clin Oncol J Am Soc Clin Oncol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:57:52Z","timestamp":1761857872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2274580725003334"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100391","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of recent approvals on future alzheimer\u2019s disease clinical development: Statistical considerations for combination trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100391"}}